These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 28115161)

  • 21. BET Bromodomain Inhibition as a Therapeutic Strategy in Ovarian Cancer by Downregulating FoxM1.
    Zhang Z; Ma P; Jing Y; Yan Y; Cai MC; Zhang M; Zhang S; Peng H; Ji ZL; Di W; Gu Z; Gao WQ; Zhuang G
    Theranostics; 2016; 6(2):219-30. PubMed ID: 26877780
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Suppression of BRD4 inhibits human hepatocellular carcinoma by repressing MYC and enhancing BIM expression.
    Li GQ; Guo WZ; Zhang Y; Seng JJ; Zhang HP; Ma XX; Zhang G; Li J; Yan B; Tang HW; Li SS; Wang LD; Zhang SJ
    Oncotarget; 2016 Jan; 7(3):2462-74. PubMed ID: 26575167
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Discovery of a series of dihydroquinoxalin-2(1H)-ones as selective BET inhibitors from a dual PLK1-BRD4 inhibitor.
    Hu J; Wang Y; Li Y; Xu L; Cao D; Song S; Damaneh MS; Wang X; Meng T; Chen YL; Shen J; Miao Z; Xiong B
    Eur J Med Chem; 2017 Sep; 137():176-195. PubMed ID: 28586718
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Discovery of novel BET inhibitors by drug repurposing of nitroxoline and its analogues.
    Jiang H; Xing J; Wang C; Zhang H; Yue L; Wan X; Chen W; Ding H; Xie Y; Tao H; Chen Z; Jiang H; Chen K; Chen S; Zheng M; Zhang Y; Luo C
    Org Biomol Chem; 2017 Nov; 15(44):9352-9361. PubMed ID: 29087414
    [TBL] [Abstract][Full Text] [Related]  

  • 25. BRD4 inhibition suppresses cell growth, migration and invasion of salivary adenoid cystic carcinoma.
    Wang L; Wu X; Wang R; Yang C; Li Z; Wang C; Zhang F; Yang P
    Biol Res; 2017 May; 50(1):19. PubMed ID: 28545522
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A natural compound, aristoyagonine, is identified as a potent bromodomain inhibitor by mid-throughput screening.
    Kim YH; Kim M; Yoo M; Kim JE; Lee HK; Heo JN; Lee CO; Yoo M; Jung KY; Yun CS; Moon SW; Chang HK; Chung CW; Pyo S; Choi SU; Park CH
    Biochem Biophys Res Commun; 2018 Sep; 503(2):882-887. PubMed ID: 29928885
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PI3KCA plays a major role in multiple myeloma and its inhibition with BYL719 decreases proliferation, synergizes with other therapies and overcomes stroma-induced resistance.
    Azab F; Vali S; Abraham J; Potter N; Muz B; de la Puente P; Fiala M; Paasch J; Sultana Z; Tyagi A; Abbasi T; Vij R; Azab AK
    Br J Haematol; 2014 Apr; 165(1):89-101. PubMed ID: 24405121
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs.
    Boi M; Gaudio E; Bonetti P; Kwee I; Bernasconi E; Tarantelli C; Rinaldi A; Testoni M; Cascione L; Ponzoni M; Mensah AA; Stathis A; Stussi G; Riveiro ME; Herait P; Inghirami G; Cvitkovic E; Zucca E; Bertoni F
    Clin Cancer Res; 2015 Apr; 21(7):1628-38. PubMed ID: 25623213
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibition of BRD4 suppresses tumor growth and enhances iodine uptake in thyroid cancer.
    Gao X; Wu X; Zhang X; Hua W; Zhang Y; Maimaiti Y; Gao Z; Zhang Y
    Biochem Biophys Res Commun; 2016 Jan; 469(3):679-85. PubMed ID: 26707881
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Potent antimyeloma activity of the novel bromodomain inhibitors I-BET151 and I-BET762.
    Chaidos A; Caputo V; Gouvedenou K; Liu B; Marigo I; Chaudhry MS; Rotolo A; Tough DF; Smithers NN; Bassil AK; Chapman TD; Harker NR; Barbash O; Tummino P; Al-Mahdi N; Haynes AC; Cutler L; Le B; Rahemtulla A; Roberts I; Kleijnen M; Witherington JJ; Parr NJ; Prinjha RK; Karadimitris A
    Blood; 2014 Jan; 123(5):697-705. PubMed ID: 24335499
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Small molecule inhibitor screen identifies synergistic activity of the bromodomain inhibitor CPI203 and bortezomib in drug resistant myeloma.
    Siegel MB; Liu SQ; Davare MA; Spurgeon SE; Loriaux MM; Druker BJ; Scott EC; Tyner JW
    Oncotarget; 2015 Aug; 6(22):18921-32. PubMed ID: 26254279
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 4-Hydroxytamoxifen inhibits proliferation of multiple myeloma cells in vitro through down-regulation of c-Myc, up-regulation of p27Kip1, and modulation of Bcl-2 family members.
    Gauduchon J; Gouilleux F; Maillard S; Marsaud V; Renoir JM; Sola B
    Clin Cancer Res; 2005 Mar; 11(6):2345-54. PubMed ID: 15788686
    [TBL] [Abstract][Full Text] [Related]  

  • 33. BRD4-targeted therapy induces Myc-independent cytotoxicity in Gnaq/11-mutatant uveal melanoma cells.
    Ambrosini G; Sawle AD; Musi E; Schwartz GK
    Oncotarget; 2015 Oct; 6(32):33397-409. PubMed ID: 26397223
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rational design of 5-((1H-imidazol-1-yl)methyl)quinolin-8-ol derivatives as novel bromodomain-containing protein 4 inhibitors.
    Xing J; Zhang R; Jiang X; Hu T; Wang X; Qiao G; Wang J; Yang F; Luo X; Chen K; Shen J; Luo C; Jiang H; Zheng M
    Eur J Med Chem; 2019 Feb; 163():281-294. PubMed ID: 30529546
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting bromodomain-containing protein 4 (BRD4) benefits rheumatoid arthritis.
    Zhang QG; Qian J; Zhu YC
    Immunol Lett; 2015 Aug; 166(2):103-8. PubMed ID: 26093279
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of a Benzoisoxazoloazepine Inhibitor (CPI-0610) of the Bromodomain and Extra-Terminal (BET) Family as a Candidate for Human Clinical Trials.
    Albrecht BK; Gehling VS; Hewitt MC; Vaswani RG; Côté A; Leblanc Y; Nasveschuk CG; Bellon S; Bergeron L; Campbell R; Cantone N; Cooper MR; Cummings RT; Jayaram H; Joshi S; Mertz JA; Neiss A; Normant E; O'Meara M; Pardo E; Poy F; Sandy P; Supko J; Sims RJ; Harmange JC; Taylor AM; Audia JE
    J Med Chem; 2016 Feb; 59(4):1330-9. PubMed ID: 26815195
    [TBL] [Abstract][Full Text] [Related]  

  • 37. BET Bromodomain Blockade Mitigates Intimal Hyperplasia in Rat Carotid Arteries.
    Wang B; Zhang M; Takayama T; Shi X; Roenneburg DA; Kent KC; Guo LW
    EBioMedicine; 2015 Nov; 2(11):1650-61. PubMed ID: 26870791
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mapping the chemical chromatin reactivation landscape identifies BRD4-TAF1 cross-talk.
    Sdelci S; Lardeau CH; Tallant C; Klepsch F; Klaiber B; Bennett J; Rathert P; Schuster M; Penz T; Fedorov O; Superti-Furga G; Bock C; Zuber J; Huber KV; Knapp S; Müller S; Kubicek S
    Nat Chem Biol; 2016 Jul; 12(7):504-10. PubMed ID: 27159579
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Discovery of novel BRD4 inhibitors by high-throughput screening, crystallography, and cell-based assays.
    Sun Z; Zhang H; Chen Z; Xie Y; Jiang H; Chen L; Ding H; Zhang Y; Jiang H; Zheng M; Luo C
    Bioorg Med Chem Lett; 2017 May; 27(9):2003-2009. PubMed ID: 28347667
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting Cancer Cells with BET Bromodomain Inhibitors.
    Xu Y; Vakoc CR
    Cold Spring Harb Perspect Med; 2017 Jul; 7(7):. PubMed ID: 28213432
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.